MX391776B - Métodos relacionados con células pluripotentes. - Google Patents

Métodos relacionados con células pluripotentes.

Info

Publication number
MX391776B
MX391776B MX2016012102A MX2016012102A MX391776B MX 391776 B MX391776 B MX 391776B MX 2016012102 A MX2016012102 A MX 2016012102A MX 2016012102 A MX2016012102 A MX 2016012102A MX 391776 B MX391776 B MX 391776B
Authority
MX
Mexico
Prior art keywords
pluripotent cells
methods related
methods
assays
assume
Prior art date
Application number
MX2016012102A
Other languages
English (en)
Other versions
MX2016012102A (es
Inventor
Charles A Vacanti
Koji Kojima
Original Assignee
Vcell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vcell Therapeutics Inc filed Critical Vcell Therapeutics Inc
Publication of MX2016012102A publication Critical patent/MX2016012102A/es
Publication of MX391776B publication Critical patent/MX391776B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a un método in vitro para incrementar el número de células expresan uno o más marcadores de pluripotencia en una población de células que comprende células somáticas de mamíferos diferenciadas normales no embrionarias, no transformadas, el método caracterizado porque comprende; someter la población de células somáticas a una cantidad eficaz de estrés químico que comprende ATP a una concentración de entre 20 µM y 200 mM, solo o en combinación con un estrés mecánico para incrementar los niveles de genes inducibles por estrés en una cantidad y por un tiempo eficaz para incrementar el número de células que expresan uno o más marcadores de pluripotencia, en donde las células están a un pH de entre 4.6 y 6.0, sin introducción de un gen exógeno, una transcripción, una proteína, un componente nuclear o citoplasma, o sin fusión celular, en donde uno o más marcadores de pluripotencia seleccionados del grupo que consiste en SSEA, y Sox2, aumentado así el número de células que expresan los marcadores pluripotencia.
MX2016012102A 2014-03-19 2015-03-19 Métodos relacionados con células pluripotentes. MX391776B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461955362P 2014-03-19 2014-03-19
US201461955358P 2014-03-19 2014-03-19
US201462043042P 2014-08-28 2014-08-28
PCT/US2015/021418 WO2015143125A1 (en) 2014-03-19 2015-03-19 Methods relating to pluripotent cells

Publications (2)

Publication Number Publication Date
MX2016012102A MX2016012102A (es) 2017-02-20
MX391776B true MX391776B (es) 2025-03-11

Family

ID=54145305

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012102A MX391776B (es) 2014-03-19 2015-03-19 Métodos relacionados con células pluripotentes.
MX2022000516A MX2022000516A (es) 2014-03-19 2016-09-19 Metodos relacionados con celulas pluripotentes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000516A MX2022000516A (es) 2014-03-19 2016-09-19 Metodos relacionados con celulas pluripotentes.

Country Status (13)

Country Link
US (2) US11242508B2 (es)
EP (1) EP3119877B1 (es)
JP (5) JP2017513517A (es)
KR (2) KR102443578B1 (es)
CN (2) CN106459897A (es)
AU (2) AU2015231258B2 (es)
BR (1) BR112016021395A8 (es)
CA (1) CA2943164C (es)
ES (1) ES3006707T3 (es)
IL (1) IL247890B2 (es)
MX (2) MX391776B (es)
RU (1) RU2711942C2 (es)
WO (1) WO2015143125A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855967B1 (ko) 2016-03-11 2018-05-10 가톨릭관동대학교산학협력단 물리적 자극에 의한 환경유입을 이용한 세포 리프로그래밍 방법
US20210060163A1 (en) 2019-09-04 2021-03-04 Vcell Therapeutics, Inc. Vaccine for treatment of cancer and method of making by stress reprogramming
JP7417619B2 (ja) * 2019-10-04 2024-01-18 京セラ株式会社 ｐＨ測定方法およびｐＨ測定装置
CN110964696B (zh) * 2019-10-16 2023-02-03 南通大学 乳酸/酸性环境促进无致瘤性的淋巴母细胞去分化获得致瘤性的研究方法
US20220090022A1 (en) * 2020-02-11 2022-03-24 Board Of Regents, The University Of Texas System Generating induced pluripotent stem cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
FR2687404B1 (fr) * 1992-02-19 1994-05-20 Centre Nal Recherc Scientifique Peptides immunologiquement apparentes aux proteines d'un agent viral et leurs applications biologiques.
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
WO2005065354A2 (en) * 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
CA2561690A1 (en) * 2004-03-30 2005-10-27 Kyoto University Process for producing multipotential stem cell originating in testoid cell
WO2006029084A2 (en) * 2004-09-03 2006-03-16 Cornell Research Foundation, Inc. Bone marrow derived oct3/4+ stem cells
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20070190646A1 (en) 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
EP2626416A3 (en) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Reprogramming of somatic cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
KR20120002134A (ko) 2010-06-30 2012-01-05 서울대학교산학협력단 지방 기질 세포의 역분화를 유도하는 방법
WO2012006587A2 (en) * 2010-07-09 2012-01-12 The Gid Group, Inc. Apparatus and methods relating to collecting and processing human biological material containing adipose
CA2824553A1 (en) * 2011-01-19 2012-07-26 The Regents Of The University Of California Somatic cells with innate potential for pluripotency
WO2012112458A2 (en) * 2011-02-14 2012-08-23 The Regents Of The University Of California Compositions and methods for increasing reprogramming efficiency
WO2012121577A2 (ko) * 2011-03-10 2012-09-13 이화여자대학교 산학협력단 Ｐｔｅｎ을 포함하는 줄기세포의 조직 재생능 강화용 조성물
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
AU2013251649B2 (en) 2012-04-24 2019-04-04 Vcell Therapeutics, Inc. Generating pluripotent cells de novo

Also Published As

Publication number Publication date
RU2016140698A3 (es) 2019-03-01
NZ725337A (en) 2024-01-26
EP3119877A4 (en) 2017-10-18
EP3119877A1 (en) 2017-01-25
AU2015231258A1 (en) 2016-11-03
MX2016012102A (es) 2017-02-20
MX2022000516A (es) 2022-04-20
JP2020172539A (ja) 2020-10-22
JP2023011931A (ja) 2023-01-24
JP2025094131A (ja) 2025-06-24
AU2021286294B2 (en) 2023-12-07
CN106459897A (zh) 2017-02-22
JP2017513517A (ja) 2017-06-01
JP2022043344A (ja) 2022-03-15
IL247890B2 (en) 2024-08-01
AU2021286294A1 (en) 2022-01-06
RU2711942C2 (ru) 2020-01-23
EP3119877B1 (en) 2024-10-23
CN112111446A (zh) 2020-12-22
NZ761670A (en) 2024-04-26
BR112016021395A8 (pt) 2021-07-13
AU2015231258B2 (en) 2021-10-07
KR20210141776A (ko) 2021-11-23
RU2016140698A (ru) 2018-04-23
CA2943164C (en) 2024-03-19
CA2943164A1 (en) 2015-09-24
US20220064593A1 (en) 2022-03-03
IL247890A0 (en) 2016-11-30
KR102327986B1 (ko) 2021-11-18
BR112016021395A2 (pt) 2017-08-15
ES3006707T3 (en) 2025-03-18
US11242508B2 (en) 2022-02-08
KR20160145033A (ko) 2016-12-19
KR102443578B1 (ko) 2022-09-16
US20170002314A1 (en) 2017-01-05
IL247890B1 (en) 2024-04-01
WO2015143125A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
IL268597A (en) Methods of targeted genetic alteration in plant cells
SA518391159B1 (ar) مترافقات الألفة- قليلة النيوكليوتيد واستخداماتها
SG10201809901SA (en) Generating Pluripotent Cells De Novo
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
MA39819A (fr) Méthodes et compositions d'immunomodulation
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
BR112017013481A2 (pt) material permeável a gás
MX2020009670A (es) Metodos de cultivo por perfusion y usos de los mismos.
EP3448982A4 (en) CELL CULTURE MEDIUM
EP3561043A4 (en) CELL CULTURE SUBSTRATE
EP3324982A4 (en) HEMATOPOIETIC STEM CELLS EXPRESSING PD-L1 AND USES
DK3253863T3 (da) Bioreaktorsystem til celledyrkning
EP3655523C0 (en) CELL CULTURE MATERIALS
DK3766582T3 (da) Cellekultur
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2016015893A (es) Produccion de fragmentos de fragmento cristalizable (fc).
EP3448986A4 (en) CELL CULTURE
MX2022000516A (es) Metodos relacionados con celulas pluripotentes.
EP3561042A4 (en) SCAFFOLDING MATERIAL FOR CELL CULTURE
IL270880A (en) Cell culture methods
WO2015171852A3 (en) Methods and compositions for non-cytotoxic stem cell transplantation
DE112017006675A5 (de) PEM-Brennstoffzelle
EP3106548A4 (en) Active-ester-group-containing composition for producing fibers, and cell culture scaffold material using fibers produced from active-ester-group-containing composition